Predictive value of nutritional indicators with regard to the survival outcomes in patients with metastatic esophageal squamous cell carcinoma treated with camrelizumab
Nutritional indicators have been implicated in the survival outcomes of various malignant tumors. However, there are few studies on the association between nutritional indicators and immunotherapy for esophageal cancer. The present study aimed to explore the value of nutritional indicators with rega...
Gespeichert in:
| Veröffentlicht in: | Oncology letters 2023-05, Vol.25 (5), p.198, Article 198 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 5 |
| container_start_page | 198 |
| container_title | Oncology letters |
| container_volume | 25 |
| creator | Liu, Jiang Hu, Guangyin Zhai, Chentong Wang, Jingjing Xu, Wenjing Xie, Jun Zhu, Wugang Jiang, Ping Liu, Degan |
| description | Nutritional indicators have been implicated in the survival outcomes of various malignant tumors. However, there are few studies on the association between nutritional indicators and immunotherapy for esophageal cancer. The present study aimed to explore the value of nutritional indicators with regard to the survival outcomes in patients with metastatic esophageal squamous cell carcinoma (ESCC) treated with camrelizumab. A retrospective cohort analysis of 158 metastatic ESCC patients treated with camrelizumab in The Affiliated Xinghua People's Hospital, Medical School of Yangzhou University (Xinghua, China) between September 2019 and July 2022 was conducted. A receiver operating characteristic curve was used to determine the optimal cut-off values of prognostic nutritional index (PNI) and albumin (ALB). The cut-off value for body mass index (BMI) was set at the normal lower limit (18.5 kg/m
). Progression-free survival (PFS) and overall survival (OS) were evaluated using the Kaplan-Meier method, and the differences in PFS or OS between groups were compared using the log-rank test. The prognostic value of each variable was analyzed based on the univariate and multivariate Cox proportional hazards regression models. The optimal cutoff values of PNI, ALB and BMI were 41.35, 36.8 g/l and 18.5 kg/m
, respectively. Lower PNI, ALB and BMI were closely associated with shorter PFS [hazard ratio (HR) for PNI, 3.599; P |
| doi_str_mv | 10.3892/ol.2023.13784 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10126655</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A748650527</galeid><sourcerecordid>A748650527</sourcerecordid><originalsourceid>FETCH-LOGICAL-c514t-a33be7c7abec05a6967f665120937ea6f4428b3564ea45d68da0a5c9f19183963</originalsourceid><addsrcrecordid>eNptkk1v1DAQhiMEolXpkSuyhMQtix0nTnJCVUUBqRIc4GxNnMnGlR1v_bEV_CJ-Zr3ssnQl7IOtmed9rRlPUbxmdMW7vnrvzKqiFV8x3nb1s-KctX1VMtpVz4_3tj4rLkO4o3k1gnWdeFmc8ZYxXtP6vPj9zeOoVdRbJFswCYmbyJKi11G7BQzRS05DdD6QBx1n4nENfiTRkTgjCclvddYRl6JyFkPmyQaixiUeBBYjhJhDimBwmxnWmPlwn8C6FIhCY4gCr_TiLJDoESKOe6kC69HoX8nC8Kp4MYEJeHk4L4ofNx-_X38ub79--nJ9dVuqhtWxBM4HbFULAyragOhFOwnRsIr2vEUQU11X3cAbUSPUzSi6ESg0qp9YzzreC35RfNj7btJgcVS5EA9Gbry24H9KB1qeZhY9y7XbSkZZlV9qssPbg4N39wlDlHcu-dzLIKuOCtGzfPyj1mBQ6mVy2U1ZHZS8autONLSp2kyt_kPlPaLVyi046Rw_Ebx7Iphzq-McnEm73wynYLkHlXcheJyOJTIqd8MlnZG74ZJ_hivzb5725Uj_HSX-CJY8zYg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2806691280</pqid></control><display><type>article</type><title>Predictive value of nutritional indicators with regard to the survival outcomes in patients with metastatic esophageal squamous cell carcinoma treated with camrelizumab</title><source>Spandidos Publications Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Liu, Jiang ; Hu, Guangyin ; Zhai, Chentong ; Wang, Jingjing ; Xu, Wenjing ; Xie, Jun ; Zhu, Wugang ; Jiang, Ping ; Liu, Degan</creator><creatorcontrib>Liu, Jiang ; Hu, Guangyin ; Zhai, Chentong ; Wang, Jingjing ; Xu, Wenjing ; Xie, Jun ; Zhu, Wugang ; Jiang, Ping ; Liu, Degan</creatorcontrib><description><![CDATA[Nutritional indicators have been implicated in the survival outcomes of various malignant tumors. However, there are few studies on the association between nutritional indicators and immunotherapy for esophageal cancer. The present study aimed to explore the value of nutritional indicators with regard to the survival outcomes in patients with metastatic esophageal squamous cell carcinoma (ESCC) treated with camrelizumab. A retrospective cohort analysis of 158 metastatic ESCC patients treated with camrelizumab in The Affiliated Xinghua People's Hospital, Medical School of Yangzhou University (Xinghua, China) between September 2019 and July 2022 was conducted. A receiver operating characteristic curve was used to determine the optimal cut-off values of prognostic nutritional index (PNI) and albumin (ALB). The cut-off value for body mass index (BMI) was set at the normal lower limit (18.5 kg/m
). Progression-free survival (PFS) and overall survival (OS) were evaluated using the Kaplan-Meier method, and the differences in PFS or OS between groups were compared using the log-rank test. The prognostic value of each variable was analyzed based on the univariate and multivariate Cox proportional hazards regression models. The optimal cutoff values of PNI, ALB and BMI were 41.35, 36.8 g/l and 18.5 kg/m
, respectively. Lower PNI, ALB and BMI were closely associated with shorter PFS [hazard ratio (HR) for PNI, 3.599; P<0.001; HR for ALB, 4.148; P<0.001; HR for BMI, 5.623; P<0.001) and OS (HR for PNI, 7.605; P<0.001; HR for ALB, 7.852; P<0.001; HR for BMI, 7.915; P<0.001) times. Univariate and multivariate Cox regression analyses indicated that lower PNI, ALB and BMI were independent risk factors of PFS and OS in patients with metastatic ESCC receiving camrelizumab treatment. In conclusion, PNI, ALB and BMI are promising predictive indicators to assess the survival outcomes in patients with metastatic ESCC treated with camrelizumab. Moreover, PNI, ALB and BMI may have prognostic significance in these patients.]]></description><identifier>ISSN: 1792-1074</identifier><identifier>EISSN: 1792-1082</identifier><identifier>DOI: 10.3892/ol.2023.13784</identifier><identifier>PMID: 37113404</identifier><language>eng</language><publisher>Greece: Spandidos Publications</publisher><subject>Biomarkers ; Body mass index ; Cancer ; Cancer therapies ; Care and treatment ; Chemotherapy ; Clinical medicine ; Development and progression ; Esophageal cancer ; Hematology ; Immunotherapy ; Inhibitor drugs ; Lymphocytes ; Medical colleges ; Medical prognosis ; Metastasis ; Monoclonal antibodies ; Oncology ; Oncology, Experimental ; Patient outcomes ; Patients ; Squamous cell carcinoma ; Targeted cancer therapy ; Tumors</subject><ispartof>Oncology letters, 2023-05, Vol.25 (5), p.198, Article 198</ispartof><rights>Copyright: © Liu et al.</rights><rights>COPYRIGHT 2023 Spandidos Publications</rights><rights>Copyright Spandidos Publications UK Ltd. 2023</rights><rights>Copyright: © Liu et al. 2023</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c514t-a33be7c7abec05a6967f665120937ea6f4428b3564ea45d68da0a5c9f19183963</citedby><cites>FETCH-LOGICAL-c514t-a33be7c7abec05a6967f665120937ea6f4428b3564ea45d68da0a5c9f19183963</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10126655/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10126655/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37113404$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Liu, Jiang</creatorcontrib><creatorcontrib>Hu, Guangyin</creatorcontrib><creatorcontrib>Zhai, Chentong</creatorcontrib><creatorcontrib>Wang, Jingjing</creatorcontrib><creatorcontrib>Xu, Wenjing</creatorcontrib><creatorcontrib>Xie, Jun</creatorcontrib><creatorcontrib>Zhu, Wugang</creatorcontrib><creatorcontrib>Jiang, Ping</creatorcontrib><creatorcontrib>Liu, Degan</creatorcontrib><title>Predictive value of nutritional indicators with regard to the survival outcomes in patients with metastatic esophageal squamous cell carcinoma treated with camrelizumab</title><title>Oncology letters</title><addtitle>Oncol Lett</addtitle><description><![CDATA[Nutritional indicators have been implicated in the survival outcomes of various malignant tumors. However, there are few studies on the association between nutritional indicators and immunotherapy for esophageal cancer. The present study aimed to explore the value of nutritional indicators with regard to the survival outcomes in patients with metastatic esophageal squamous cell carcinoma (ESCC) treated with camrelizumab. A retrospective cohort analysis of 158 metastatic ESCC patients treated with camrelizumab in The Affiliated Xinghua People's Hospital, Medical School of Yangzhou University (Xinghua, China) between September 2019 and July 2022 was conducted. A receiver operating characteristic curve was used to determine the optimal cut-off values of prognostic nutritional index (PNI) and albumin (ALB). The cut-off value for body mass index (BMI) was set at the normal lower limit (18.5 kg/m
). Progression-free survival (PFS) and overall survival (OS) were evaluated using the Kaplan-Meier method, and the differences in PFS or OS between groups were compared using the log-rank test. The prognostic value of each variable was analyzed based on the univariate and multivariate Cox proportional hazards regression models. The optimal cutoff values of PNI, ALB and BMI were 41.35, 36.8 g/l and 18.5 kg/m
, respectively. Lower PNI, ALB and BMI were closely associated with shorter PFS [hazard ratio (HR) for PNI, 3.599; P<0.001; HR for ALB, 4.148; P<0.001; HR for BMI, 5.623; P<0.001) and OS (HR for PNI, 7.605; P<0.001; HR for ALB, 7.852; P<0.001; HR for BMI, 7.915; P<0.001) times. Univariate and multivariate Cox regression analyses indicated that lower PNI, ALB and BMI were independent risk factors of PFS and OS in patients with metastatic ESCC receiving camrelizumab treatment. In conclusion, PNI, ALB and BMI are promising predictive indicators to assess the survival outcomes in patients with metastatic ESCC treated with camrelizumab. Moreover, PNI, ALB and BMI may have prognostic significance in these patients.]]></description><subject>Biomarkers</subject><subject>Body mass index</subject><subject>Cancer</subject><subject>Cancer therapies</subject><subject>Care and treatment</subject><subject>Chemotherapy</subject><subject>Clinical medicine</subject><subject>Development and progression</subject><subject>Esophageal cancer</subject><subject>Hematology</subject><subject>Immunotherapy</subject><subject>Inhibitor drugs</subject><subject>Lymphocytes</subject><subject>Medical colleges</subject><subject>Medical prognosis</subject><subject>Metastasis</subject><subject>Monoclonal antibodies</subject><subject>Oncology</subject><subject>Oncology, Experimental</subject><subject>Patient outcomes</subject><subject>Patients</subject><subject>Squamous cell carcinoma</subject><subject>Targeted cancer therapy</subject><subject>Tumors</subject><issn>1792-1074</issn><issn>1792-1082</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNptkk1v1DAQhiMEolXpkSuyhMQtix0nTnJCVUUBqRIc4GxNnMnGlR1v_bEV_CJ-Zr3ssnQl7IOtmed9rRlPUbxmdMW7vnrvzKqiFV8x3nb1s-KctX1VMtpVz4_3tj4rLkO4o3k1gnWdeFmc8ZYxXtP6vPj9zeOoVdRbJFswCYmbyJKi11G7BQzRS05DdD6QBx1n4nENfiTRkTgjCclvddYRl6JyFkPmyQaixiUeBBYjhJhDimBwmxnWmPlwn8C6FIhCY4gCr_TiLJDoESKOe6kC69HoX8nC8Kp4MYEJeHk4L4ofNx-_X38ub79--nJ9dVuqhtWxBM4HbFULAyragOhFOwnRsIr2vEUQU11X3cAbUSPUzSi6ESg0qp9YzzreC35RfNj7btJgcVS5EA9Gbry24H9KB1qeZhY9y7XbSkZZlV9qssPbg4N39wlDlHcu-dzLIKuOCtGzfPyj1mBQ6mVy2U1ZHZS8autONLSp2kyt_kPlPaLVyi046Rw_Ebx7Iphzq-McnEm73wynYLkHlXcheJyOJTIqd8MlnZG74ZJ_hivzb5725Uj_HSX-CJY8zYg</recordid><startdate>20230501</startdate><enddate>20230501</enddate><creator>Liu, Jiang</creator><creator>Hu, Guangyin</creator><creator>Zhai, Chentong</creator><creator>Wang, Jingjing</creator><creator>Xu, Wenjing</creator><creator>Xie, Jun</creator><creator>Zhu, Wugang</creator><creator>Jiang, Ping</creator><creator>Liu, Degan</creator><general>Spandidos Publications</general><general>Spandidos Publications UK Ltd</general><general>D.A. Spandidos</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope></search><sort><creationdate>20230501</creationdate><title>Predictive value of nutritional indicators with regard to the survival outcomes in patients with metastatic esophageal squamous cell carcinoma treated with camrelizumab</title><author>Liu, Jiang ; Hu, Guangyin ; Zhai, Chentong ; Wang, Jingjing ; Xu, Wenjing ; Xie, Jun ; Zhu, Wugang ; Jiang, Ping ; Liu, Degan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c514t-a33be7c7abec05a6967f665120937ea6f4428b3564ea45d68da0a5c9f19183963</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Biomarkers</topic><topic>Body mass index</topic><topic>Cancer</topic><topic>Cancer therapies</topic><topic>Care and treatment</topic><topic>Chemotherapy</topic><topic>Clinical medicine</topic><topic>Development and progression</topic><topic>Esophageal cancer</topic><topic>Hematology</topic><topic>Immunotherapy</topic><topic>Inhibitor drugs</topic><topic>Lymphocytes</topic><topic>Medical colleges</topic><topic>Medical prognosis</topic><topic>Metastasis</topic><topic>Monoclonal antibodies</topic><topic>Oncology</topic><topic>Oncology, Experimental</topic><topic>Patient outcomes</topic><topic>Patients</topic><topic>Squamous cell carcinoma</topic><topic>Targeted cancer therapy</topic><topic>Tumors</topic><toplevel>online_resources</toplevel><creatorcontrib>Liu, Jiang</creatorcontrib><creatorcontrib>Hu, Guangyin</creatorcontrib><creatorcontrib>Zhai, Chentong</creatorcontrib><creatorcontrib>Wang, Jingjing</creatorcontrib><creatorcontrib>Xu, Wenjing</creatorcontrib><creatorcontrib>Xie, Jun</creatorcontrib><creatorcontrib>Zhu, Wugang</creatorcontrib><creatorcontrib>Jiang, Ping</creatorcontrib><creatorcontrib>Liu, Degan</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Oncology letters</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Liu, Jiang</au><au>Hu, Guangyin</au><au>Zhai, Chentong</au><au>Wang, Jingjing</au><au>Xu, Wenjing</au><au>Xie, Jun</au><au>Zhu, Wugang</au><au>Jiang, Ping</au><au>Liu, Degan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Predictive value of nutritional indicators with regard to the survival outcomes in patients with metastatic esophageal squamous cell carcinoma treated with camrelizumab</atitle><jtitle>Oncology letters</jtitle><addtitle>Oncol Lett</addtitle><date>2023-05-01</date><risdate>2023</risdate><volume>25</volume><issue>5</issue><spage>198</spage><pages>198-</pages><artnum>198</artnum><issn>1792-1074</issn><eissn>1792-1082</eissn><abstract><![CDATA[Nutritional indicators have been implicated in the survival outcomes of various malignant tumors. However, there are few studies on the association between nutritional indicators and immunotherapy for esophageal cancer. The present study aimed to explore the value of nutritional indicators with regard to the survival outcomes in patients with metastatic esophageal squamous cell carcinoma (ESCC) treated with camrelizumab. A retrospective cohort analysis of 158 metastatic ESCC patients treated with camrelizumab in The Affiliated Xinghua People's Hospital, Medical School of Yangzhou University (Xinghua, China) between September 2019 and July 2022 was conducted. A receiver operating characteristic curve was used to determine the optimal cut-off values of prognostic nutritional index (PNI) and albumin (ALB). The cut-off value for body mass index (BMI) was set at the normal lower limit (18.5 kg/m
). Progression-free survival (PFS) and overall survival (OS) were evaluated using the Kaplan-Meier method, and the differences in PFS or OS between groups were compared using the log-rank test. The prognostic value of each variable was analyzed based on the univariate and multivariate Cox proportional hazards regression models. The optimal cutoff values of PNI, ALB and BMI were 41.35, 36.8 g/l and 18.5 kg/m
, respectively. Lower PNI, ALB and BMI were closely associated with shorter PFS [hazard ratio (HR) for PNI, 3.599; P<0.001; HR for ALB, 4.148; P<0.001; HR for BMI, 5.623; P<0.001) and OS (HR for PNI, 7.605; P<0.001; HR for ALB, 7.852; P<0.001; HR for BMI, 7.915; P<0.001) times. Univariate and multivariate Cox regression analyses indicated that lower PNI, ALB and BMI were independent risk factors of PFS and OS in patients with metastatic ESCC receiving camrelizumab treatment. In conclusion, PNI, ALB and BMI are promising predictive indicators to assess the survival outcomes in patients with metastatic ESCC treated with camrelizumab. Moreover, PNI, ALB and BMI may have prognostic significance in these patients.]]></abstract><cop>Greece</cop><pub>Spandidos Publications</pub><pmid>37113404</pmid><doi>10.3892/ol.2023.13784</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1792-1074 |
| ispartof | Oncology letters, 2023-05, Vol.25 (5), p.198, Article 198 |
| issn | 1792-1074 1792-1082 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10126655 |
| source | Spandidos Publications Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| subjects | Biomarkers Body mass index Cancer Cancer therapies Care and treatment Chemotherapy Clinical medicine Development and progression Esophageal cancer Hematology Immunotherapy Inhibitor drugs Lymphocytes Medical colleges Medical prognosis Metastasis Monoclonal antibodies Oncology Oncology, Experimental Patient outcomes Patients Squamous cell carcinoma Targeted cancer therapy Tumors |
| title | Predictive value of nutritional indicators with regard to the survival outcomes in patients with metastatic esophageal squamous cell carcinoma treated with camrelizumab |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T05%3A38%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Predictive%20value%20of%20nutritional%20indicators%20with%20regard%20to%20the%20survival%20outcomes%20in%20patients%20with%20metastatic%20esophageal%20squamous%20cell%20carcinoma%20treated%20with%20camrelizumab&rft.jtitle=Oncology%20letters&rft.au=Liu,%20Jiang&rft.date=2023-05-01&rft.volume=25&rft.issue=5&rft.spage=198&rft.pages=198-&rft.artnum=198&rft.issn=1792-1074&rft.eissn=1792-1082&rft_id=info:doi/10.3892/ol.2023.13784&rft_dat=%3Cgale_pubme%3EA748650527%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2806691280&rft_id=info:pmid/37113404&rft_galeid=A748650527&rfr_iscdi=true |